UOB Kay Hian analyst Roy Chen has maintained their bullish stance on RAFLF stock, giving a Buy rating today.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Roy Chen has given his Buy rating due to a combination of factors, including Raffles Medical Group’s overall financial performance and strategic outlook. Despite a slight miss in the first half of 2025 results, the company showed growth in revenue and net profit, attributed to effective cost management and increased revenue across its business segments.
Moreover, the company is optimistic about its operations in China, expecting an EBITDA-breakeven by 2026, which indicates potential future growth. Additionally, the company’s improved cost profile, with better staff and consumable cost ratios, supports its stable financial health. These factors, combined with a target price of S$1.25, underpin Roy Chen’s Buy recommendation.
In another report released today, DBS also maintained a Buy rating on the stock with a S$1.32 price target.